Showing 7 of 7 recruiting trials for “Castleman disease”
Ruxolitinib in Previously Treated Idiopathic Multicentric Castleman Disease
👨⚕️ Joshua Brandstadter, MD, PhD, MSc, University of Pennsylvania📍 1 site📅 Started Dec 2025View details ↗
Phase II Study of Pacritinib in Kaposi Sarcoma Herpesvirus (KSHV)-Associated Multicentric Castleman Disease and KSHV-Associated Inflammatory Cytokine Syndrome (KICS)
👨⚕️ Ramya M Ramaswami, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Mar 2025View details ↗
Daratumumab for Relapsed/Refractory Primary Effusion Lymphoma, Plasmablastic Lymphoma, and Multicentric Castleman Disease
RecruitingNCT06720870 ↗
An Italian Multicenter Retrospective Observational Study to Assess Effectiveness and Safety of Siltuximab for Patients with Castleman's Disease Treated in Italy in a Real-life Context
👨⚕️ Pier Luigi Zinzani, MD, IRCCS Azienda Ospedaliero-Universitaria di Bologna📍 12 sites📅 Started Mar 2023View details ↗
RecruitingNCT05081141 ↗
HHV8 and Solid Organ Transplantation
🏥 Fondazione IRCCS Ca' Granda, Ospedale Maggiore Policlinico📍 1 site📅 Started Sep 2021View details ↗
RecruitingNCT03300830 ↗
Molecular Characterization of Viral-associated Tumors, Tumors Occurring in the Setting of HIV or Other Immune Disorders and Castleman Disease
RecruitingNCT02817997 ↗
International Registry for Patients With Castleman Disease
👨⚕️ Joshua Brandstadter, MD, PhD, MSc, University of Pennsylvania📍 1 site📅 Started Oct 2016View details ↗
Get alerts when new trials open
Create a free account to follow conditions and receive trial notifications.
Create free account →